MA52885A - Anticorps anti il-11ra - Google Patents

Anticorps anti il-11ra

Info

Publication number
MA52885A
MA52885A MA052885A MA52885A MA52885A MA 52885 A MA52885 A MA 52885A MA 052885 A MA052885 A MA 052885A MA 52885 A MA52885 A MA 52885A MA 52885 A MA52885 A MA 52885A
Authority
MA
Morocco
Prior art keywords
anti body
Prior art date
Application number
MA052885A
Other languages
English (en)
Inventor
Stuart Alexander Cook
Sebastian Schaefer
Original Assignee
Boehringer Ingelheim Int
Nat Univ Singapore
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Nat Univ Singapore, Singapore Health Serv Pte Ltd filed Critical Boehringer Ingelheim Int
Publication of MA52885A publication Critical patent/MA52885A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA052885A 2018-06-13 2019-06-13 Anticorps anti il-11ra MA52885A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1809700.6A GB201809700D0 (en) 2018-06-13 2018-06-13 IL-11 antibodies

Publications (1)

Publication Number Publication Date
MA52885A true MA52885A (fr) 2021-04-21

Family

ID=63042296

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052885A MA52885A (fr) 2018-06-13 2019-06-13 Anticorps anti il-11ra

Country Status (24)

Country Link
US (1) US11084878B2 (fr)
EP (1) EP3806959A1 (fr)
JP (1) JP7437325B2 (fr)
KR (1) KR20210031645A (fr)
CN (1) CN113226471B (fr)
AU (1) AU2019286797A1 (fr)
BR (1) BR112020025502A2 (fr)
CA (1) CA3101401A1 (fr)
CL (1) CL2020003218A1 (fr)
CO (1) CO2020015376A2 (fr)
CR (1) CR20210010A (fr)
DO (1) DOP2020000236A (fr)
EA (1) EA202092605A1 (fr)
EC (1) ECSP21001499A (fr)
GB (1) GB201809700D0 (fr)
IL (1) IL279352A (fr)
JO (1) JOP20200300A1 (fr)
MA (1) MA52885A (fr)
MX (1) MX2020013468A (fr)
PE (1) PE20211500A1 (fr)
PH (1) PH12020552229A1 (fr)
SG (1) SG11202011648UA (fr)
TW (1) TW202016140A (fr)
WO (1) WO2019238884A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
US20180186871A1 (en) 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
WO2020152122A1 (fr) 2019-01-21 2020-07-30 Singapore Health Services Pte. Ltd. Traitement d'hépatotoxicité
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
KR20220050087A (ko) 2019-05-03 2022-04-22 싱가포르 헬스 서비시즈 피티이 엘티디 대사성 질환의 치료 및 예방
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
EP3939999A1 (fr) * 2020-07-14 2022-01-19 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Anticorps neutralisant la sous-unité alpha du récepteur de l'interleukine 11 (il11ra) et leurs utilisations
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
CA3211686A1 (fr) 2021-02-26 2022-09-01 Bayer Aktiengesellschaft Inhibiteurs d'il-11 ou d'il-11 ra destines a etre utilises dans le traitement d'un saignement uterin anormal
CN119039440A (zh) * 2021-07-02 2024-11-29 来凯医药科技(上海)有限公司 活化的肝星状细胞（hsc）的消耗及其用途
WO2023006765A1 (fr) 2021-07-26 2023-02-02 Boehringer Ingelheim International Gmbh Traitement et prévention d'une maladie hépatique alcoolique
JP2024532620A (ja) * 2021-08-30 2024-09-05 ラッセン・セラピューティクス１・インコーポレイテッド 抗ＩＬ－１１Ｒα抗体
CN113735975B (zh) * 2021-09-07 2022-08-12 广东东阳光药业有限公司 一种抗il-11r抗体及其应用
US20250082608A1 (en) 2021-12-16 2025-03-13 Singapore Health Services Pte Ltd. Treatment and prevention of glomerular disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1598364A1 (fr) * 2004-05-21 2005-11-23 AGIRx Limited Recepteur chimérique soluble hyper IL-11 et son utilisation
PT2953971T (pt) * 2013-02-07 2023-05-02 Csl Ltd Proteínas de ligação à il-11r e suas utilizações
EP3250609A4 (fr) * 2015-01-26 2018-07-11 The University of Chicago Agents de liaison à l'il13ra alpha 2 et leur utilisation dans le traitement du cancer
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies

Also Published As

Publication number Publication date
US11084878B2 (en) 2021-08-10
KR20210031645A (ko) 2021-03-22
CN113226471A (zh) 2021-08-06
JP7437325B2 (ja) 2024-02-22
PE20211500A1 (es) 2021-08-11
ECSP21001499A (es) 2021-03-31
SG11202011648UA (en) 2020-12-30
US20190389957A1 (en) 2019-12-26
EA202092605A1 (ru) 2021-06-01
BR112020025502A2 (pt) 2021-03-16
CL2020003218A1 (es) 2021-07-30
JP2021527086A (ja) 2021-10-11
CR20210010A (es) 2021-06-01
JOP20200300A1 (ar) 2020-11-22
AU2019286797A1 (en) 2021-01-28
GB201809700D0 (en) 2018-08-01
US20200377605A9 (en) 2020-12-03
CN113226471B (zh) 2025-01-28
IL279352A (en) 2021-01-31
EP3806959A1 (fr) 2021-04-21
CA3101401A1 (fr) 2019-12-19
CO2020015376A2 (es) 2021-04-19
TW202016140A (zh) 2020-05-01
MX2020013468A (es) 2021-04-13
PH12020552229A1 (en) 2021-06-28
WO2019238884A1 (fr) 2019-12-19
DOP2020000236A (es) 2021-10-31

Similar Documents

Publication Publication Date Title
EP3849150A4 (fr) Véhicule
DK3687994T3 (da) Gadolinium-bærende pcta-baserede kontrastmidler
DE102019201181B8 (de) Fahrzeugkarosseriestruktur
EP3635295C0 (fr) Corps de meuble
EP3712044A4 (fr) Structure de carrosserie de véhicule
EP3736029A4 (fr) Structure de raccordement
PL4017342T3 (pl) Identyfikowanie części ciała
EP3573044A4 (fr) Corps d'affichage
EP3822153A4 (fr) Véhicule
EP3836166A4 (fr) Corps composite
EP3815635A4 (fr) Cathéter
EP3470893A4 (fr) Corps d'affichage
EP3744790A4 (fr) Article moulé
EP3779631A4 (fr) Corps mobile
EP3758955C0 (fr) Roue pivotante
CL2018002238S1 (es) Vehículo
EP3744380A4 (fr) Cathéter
EP3882093A4 (fr) Véhicule
CL2018002253S1 (es) Vehículo
EP3574020A4 (fr) Anticorps anti-bêta-amyloïde
EP3744379A4 (fr) Cathéter
EP3762236B1 (fr) Corps de seringue
EP4033941C0 (fr) Ensemble support de corps
ES1238719Y (es) Cuerpo aislante
HUE064722T2 (hu) Jármû